Press Releases

Press Releases

Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets Agreement includes $5 million upfront payment and development and commercial milestones up to $172 million SOUTH SAN FRANCISCO, Calif. and SHANGHAI, June 25, 2020 /PRNewswire/ --  VistaGen
Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior Delivery, an Enhanced Therapeutic Profile and Additional Intellectual Property Protection SOUTH SAN FRANCISCO, Calif., May 27, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage
The Proposed Phase 2A Open-label Study will be Conducted in New York City SOUTH SAN FRANCISCO, Calif., May 18, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain
Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) SOUTH SAN FRANCISCO, Calif., April 28, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines
SOUTH SAN FRANCISCO, Calif., March 25, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical need, today
PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ --  VistaGen Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial results for
When given together with VistaGen's oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical
Company also Receives a Notice of Allowance from the USPTO for a New AV-101 U.S. Patent for Treatment of Dyskinesia Induced by Levodopa Therapy SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing
Multiple electrophysiological biomarkers indicate AV-101's NMDA receptor target engagement Both AV-101 doses were well-tolerated and not associated with dissociative or serious adverse events Poster presented at 2019 Annual Meeting of American College of Neuropsychopharmacology SOUTH SAN FRANCISCO,
Displaying 81 - 90 of 217